Clinical Efficacy of Atomoxetine for Methamphetamine Dependence

Completed · Phase 1/Phase 2 · Has a placebo group

Conditions studied: Methamphetamine Dependence

In brief

The purpose of this study is to examine the ability of atomoxetine compared to placebo to increase time to relapse in methamphetamine dependent volunteers. Our hypothesis is that atomoxetine will increase time before (if) the participant relapses.

Key facts

Study ID

NCT01557569

Run by

University of Arkansas

People needed

20

Starts

2012-04-01

Expected to finish

2015-07-01

Last updated by the study team

2017-02-09

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.

Where it is running

• UAMS, Psychiatric Research Institute, Center for Addiction Research — Little Rock, Arkansas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.